Preliminary Phase 1 data showed brain exposure, a half-life above 30 hours and dose-dependent IL-1β inhibition for AC Immune’s oral NLRP3 inhibitor ACI-19764.
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to